ADIM
SWTX

Alpha DNA Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Alpha DNA Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,843
Closed -$411K – 252
2024
Q3 		$411K Buy
+12,843
New +$480K 0.15% 165
2021
Q2 		– Sell
-170
Closed -$12K – 582
2021
Q1 		$12K Hold
170
– – 0.01% 282
2020
Q4 		$12K Buy
+170
New +$10.9K 0.01% 290

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Alpha DNA Investment Management's SWTX Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 12,843 shares — an estimated $411K sold.

Alpha DNA Investment Management first reported a position in SWTX in Q4 2020 and held it in 3 quarters. The position peaked at $411K in Q3 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 12,843 SpringWorks Therapeutics shares in Q4 2024, an estimated $411K.
  • Alpha DNA Investment Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 3 quarters.
  • Alpha DNA Investment Management's SpringWorks Therapeutics position peaked at $411K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.